The Prevalence of Psychosocial Distress among Cancer Patients: A Single Institution Experience at the State of Qatar

2021 ◽  
Vol 4 (2) ◽  
Keyword(s):  
Cancer Patients ◽  
Psychosocial Distress ◽  
The State ◽  
Single Institution

scholarly journals Psychosocial distress among cancer patients: A single institution experience at the state of Qatar.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e22163-e22163
Author(s):  
Azza Adel Hassan ◽  
Saad Jobran Eziada ◽  
Abdelsadiq Bashir ◽  
Amna Gameil ◽  
Hind Elmalik ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Psychosocial Distress ◽  
The State ◽  
Single Institution

Screening for psychosocial distress in pediatric cancer patients: An examination of feasibility in a single institution

2019 ◽  
Vol 36 (3) ◽  
pp. 125-137 ◽  
Author(s):  
Fiona Schulte ◽  
K. Brooke Russell ◽  
Wendy Pelletier ◽  
Laura Scott-Lane ◽  
Gregory M. T. Guilcher ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Pediatric Cancer ◽  
Psychosocial Distress ◽  
Single Institution ◽  
Pediatric Cancer Patients

scholarly journals Psychosocial Distress Among Cancer Patients: A single Institution Experience at the State of Qatar

2021 ◽  
Author(s):  
Azza Adel Hassan ◽  
Azar Naveen Saleem ◽  
Saad Jobran Eziada ◽  
Abdelsadiq Bashir ◽  
Amna Gameil ◽  
...  
Keyword(s):  
Palliative Care ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Psychosocial Distress ◽  
Disease Stage ◽  
Tumor Type ◽  
Single Institution ◽  
Cancer Treatments ◽  
Distress Level ◽  
High Distress

Abstract Introduction The prevalence of psychosocial distress is up to 45% among cancer patients. It is crucial to identify and treat distress. The aim of the study is to report on the prevalence of distress among cancer patients, analyze the variable causes of distress and to study the effect of the disease stage using the Distress Thermometer. Methods We studied distress among 3 groups, each consisting of 100 patients: those initially diagnosed, patients undergoing treatment, and patients who were referred to the palliative team. Different variables such as time of screening, sex, age, nationality, and tumor type were analyzed.Results There was an overall distress incidence of 62% (level ≥ 4) and out of that 17% of the patients had severe distress (level >7). Similarly, there was 75% of distress among patients who were referred to palliative care, compared to 56% of patients at initial diagnosis and 54% for those undergoing cancer treatments. In addition, women (69%) had more distress (53%). Expatriates had high distress, compared to Qataris (64.3% versus 51%). Breast (69%) and lung (70%) cancer patients had the highest level of distress. Physical causes of distress were the most common followed by emotional causes.Conclusion There is a substantially higher overall incidence of distress among cancer patients in Qatar. Distress should be assessed in patients at cancer diagnosis and at the time of disease progression. Screening alone isn’t enough, the different causes of distress should be identified and addressed by the appropriate interventions.

scholarly journals CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience

2021 ◽  
Vol 9 (2) ◽  
pp. 42
Author(s):  
Angeliki Andrikopoulou ◽  
Oraianthi Fiste ◽  
Kleoniki Apostolidou ◽  
Efthymia Skafida ◽  
Christos Markellos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Small Sample Size ◽  
Small Sample ◽  
Musculoskeletal Symptoms ◽  
Hematological Toxicity ◽  
Breast Cancer Patients ◽  
Single Institution ◽  
Duration Of Treatment ◽  
Positive Breast Cancer

Background: Aromatase inhibitors (AIs) are associated with musculoskeletal pain in one third (20–47%) of breast cancer patients. Recently, CDK4/6 inhibitors have emerged as a new therapeutic approach in hormone receptor (HR)-positive breast cancer. While hematological and gastrointestinal toxicities are frequently reported during treatment with CDK4/6 inhibitors, musculoskeletal symptoms are less commonly encountered. Methods: Herein, we present a retrospective study of 47 breast cancer patients who received CDK4/6 inhibitors along with endocrine therapy in our department between 01/01/2018 and 01/09/2020. Results: Median age at diagnosis was 58 years (29–81). Median duration of treatment was 8.76 months (SD: 7.68; 0.47–30.13 months). Median PFS was 24.33 months (95% CI; 1.71–46.96). Overall, toxicity was reported in 61.7% of the cases (29/47). Arthralgia was reported in 6.4% (3/47) of the patients. Hematological toxicity was reported in 51.1% (24/47) of the patients. Neutropenia was the main hematological toxicity observed (86.8%; 22/47) along with anemia (4.3%; 2/47), thrombocytopenia (2.1%; 1/47), and leukopenia (4.2%; 1/24). Conclusions: Though our data reflect a small sample size, we report a reduced arthralgia rate (6.4%) during treatment with CDK4/6 inhibitors compared with that reported in studies of AIs (20–47%).

A Unique Geographical Analysis of Lung Cancer Patients in the State of Utah

2012 ◽  
Vol 84 (3) ◽  
pp. S572
Author(s):  
R. Herde ◽  
W. Akerley ◽  
K. Kokeny ◽  
J. Ying ◽  
N. Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
The State ◽  
Geographical Analysis ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document